Genmab A/S
GMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $97 | $142 | $192 | $169 |
| - Cash | $10 | $15 | $10 | $9 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $88 | $128 | $183 | $161 |
| Revenue | $22 | $16 | $15 | $8 |
| % Growth | 30.7% | 13.6% | 72.3% | – |
| Gross Profit | $21 | $16 | $15 | $8 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| EBITDA | $10 | $6 | $7 | $4 |
| % Margin | 45% | 36.1% | 50.6% | 49.7% |
| Net Income | $8 | $4 | $5 | $3 |
| % Margin | 36.4% | 26.4% | 37.6% | 35.1% |
| EPS Diluted | 12.14 | 6.6 | 8.26 | 4.48 |
| % Growth | 83.9% | -20.1% | 84.4% | – |
| Operating Cash Flow | $8 | $7 | $4 | $2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $8 | $7 | $4 | $2 |